Calida Therapeutics

Calida Therapeutics is a preclinical-stage biotechnology company headquartered in Paris, France, with the mission of developing monoclonal antibodies to treat and prevent thrombo-inflammatory diseases. Calida aims to become a leader in this new field of thrombo-inflammatory diseases, which occur across a wide range of indications, from cardiovascular diseases to complications of autoimmune disorders. Its innovative approach seeks to disrupt the molecular link between thrombosis and inflammation by preventing crosstalk between platelets and myeloid cells, thereby eliminating the chain reaction of these two phenomena that can lead to tissue damage and life-threatening conditions.